Labcorp Holdings INC

Labcorp announced strong second-quarter results, exceeding expectations with significant revenue and EPS growth, leading to an upward revision of its full-year financial guidance.

Labcorp Holdings Inc. announced its Board of Directors has declared a cash dividend of $0.72 per share of common stock, payable on September 11, 2026.

Labcorp Holdings Inc. announced it will release its second quarter 2026 financial results on July 30, 2026, and will host a conference call and webcast to discuss the findings.

Labcorp announced its participation in the 2026 Jefferies Healthcare Conference, with a presentation scheduled for June 3rd.

Labcorp Holdings Inc. shareholders re-elected the board of directors, approved executive compensation, and ratified Deloitte & Touche LLP as the independent auditor for 2026.

Labcorp announced robust first-quarter 2026 results, exceeding expectations with significant revenue and EPS growth, leading to an upward revision of full-year financial guidance.

Labcorp Holdings Inc. announced its first-quarter 2026 financial results, reporting a 5.8% increase in total revenues to $3,537.6 million, driven by organic growth and acquisitions.

Labcorp Holdings Inc. reported a significant increase in Q3 2025 revenues and net earnings, driven by robust organic growth and strategic acquisitions across its Diagnostics and Biopharma segments.

Labcorp Holdings Inc. announced a significant increase in revenues and net earnings for the second quarter and first half of 2025, fueled by strong organic growth and strategic acquisitions across its core laboratory services.

Labcorp's Q1 2025 revenue increased by 5.3% year-over-year, driven by acquisitions and organic growth, despite unfavorable foreign currency translation.

Labcorp Holdings Inc. announced a 7.4% increase in revenue for the third quarter of 2024, driven by acquisitions and growth in its base business, while also detailing its financial position and ongoing legal matters.

Labcorp Holdings Inc. announced a 6.2% increase in revenue for the second quarter of 2024, driven by strong growth in its base business and strategic acquisitions.

Labcorp Holdings Inc. reported a 7.2% revenue increase to $13.95 billion in 2025, driven by organic growth and strategic acquisitions, while navigating healthcare cost pressures and investing in specialty testing and AI.

Labcorp's 2024 annual report reveals a 7% revenue increase, fueled by strong performance in its core diagnostics and biopharma laboratory services.

Labcorp's 2023 annual report details a 2.5% revenue increase, driven by strategic acquisitions and base business growth, alongside a focus on innovation and strategic partnerships.

Labcorp Holdings Inc. executive Kathryn W. Kyle reports transactions involving restricted stock units and common stock, including a sale under a 10b5-1 plan.

Bryan T. Vaughn, EVP and President of Diagnostics at Labcorp Holdings Inc., reported transactions involving restricted stock units and common stock.

Labcorp Holdings Inc. reports a Form 4 filing detailing the sale of common stock by EVP, Chief Legal Officer Kathryn W. Kyle.

Labcorp Holdings Inc. reports that President & CEO Adam H. Schechter sold 5,903 shares of common stock on May 11, 2026, as part of a pre-arranged 10b5-1 trading plan.

CEO Adam H. Schechter received 58,470 Labcorp shares from a 2023 performance award and withheld 26,106 shares for taxes, bringing direct holdings to 113,137.

EVP and CHRO Anita Z. Graham acquired 6,604 Labcorp shares from a vested performance award and had 2,879 shares withheld for taxes, leaving 5,185 shares owned.

Labcorp Holdings Inc. announced its 2026 Annual Meeting of Shareholders, scheduled for May 21, 2026, and provided a comprehensive overview of its 2025 performance and strategic priorities.

Labcorp Holdings Inc. announces its 2025 Annual Meeting of Shareholders, detailing proposals for director elections, executive compensation, incentive plans, and auditor ratification.

Labcorp announces its 2025 Annual Shareholder Meeting and reflects on a year of strong financial performance and strategic advancements.

Laboratory Corporation of America Holdings (Labcorp) will hold its annual shareholder meeting on May 14, 2024, to vote on key proposals including the election of directors, executive compensation, and ratification of the company's auditor.

Labcorp's 2024 proxy statement outlines the company's transformational year in 2023, marked by the successful spin-off of Fortrea and continued focus on growth opportunities.

Vanguard Capital Management disclosed a beneficial ownership of 7.52% in Labcorp Holdings Inc. as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Labcorp Holdings Inc. following an internal realignment.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.6% beneficial ownership stake in Labcorp Holdings Inc. as of March 31, 2025.